Jump to the top of the page

Showing 860 – 870 of 1307 results

  • Client Focus CEO Perspective

    Brent Gledhill discusses how William Blair’s capital markets and financial planning professionals help founders and business owners capitalize on opportunities created by their vision and leadership.

  • Secular Trends Driving Emerging Markets Growth

    The landscape for emerging markets is changing. How are these markets evolving? What are the key secular growth trends? And which markets should investors focus on?

  • Samsara Inc. Initiation

    William Blair initiated research coverage of Samsara Inc. (IOT $22.99). Samsara helps companies digitize their physical operations through its connected operations cloud, which ingests internet of things (IoT) data and provides actionable insights.

  • The Beauty Health Company Initiation

    William Blair initiated research coverage of The Beauty Health Company (SKIN $21.64). The company is a market leader in beauty health through its core asset, HydraFacial.

  • Elastic NV Initiation

    William Blair initiated research coverage of Elastic N.V. (ESTC $82.73), a provider of observability, enterprise search, and security solutions.

  • AbbVie Inc Initiation of Research Coverage

    William Blair initiated research coverage of AbbVie Inc. (ABBV $143.74).

  • Definitive Healthcare Corp Initiation

    William Blair initiated research coverage of Definitive Healthcare Corp. (DH $10.99), a leading provider of healthcare commercial intelligence data and analytics solutions.

  • Birkenstock Holding plc Initiation

    William Blair initiated research coverage of Birkenstock Holding plc (BIRK $40.20), a global brand anchored by a broad array of footwear featuring the company’s proprietary contoured footbed.

  • Adaptive Biotechnologies Corporation Initiation

    William Blair & Company initiated research coverage of Adaptive Biotechnologies Corporation (ADPT $38.01). Adaptive seeks to improve people’s lives by translating the scale and precision of its adaptive immune systems into products to help diagnose, treat, and monitor disease.

  • Actinium Pharmaceuticals, Inc. Initiation

    William Blair & Company initiated research coverage of Actinium Pharmaceuticals, Inc. (ATNM $0.21). Actinium is leading biotech company that specializes in radiopharmaceuticals.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures